RVU Ryvu Therapeutics S.A.

GPW · PL · Healthcare · Biotechnology · ryvu.com

16.00PLN+3.23%Mkt Cap: 90.76M $P/E: —Today

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's l…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap90.76M USD

Enterprise Value95.15M USD

Revenue (TTM)21.26M USD

Gross Profit12.02M USD

Net Income (TTM)-25.64M USD

Revenue/Share3.63 PLN

Last Price16.00 PLN

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees228

CountryPL

SectorHealthcare

IndustryBiotechnology

ISINPLSELVT00013

Valuation

P/E (Trailing)—

P/E (Forward)6.35

PEG—

EV/EBITDA-5.99

EV/Revenue4.48

P/S4.27

P/B12.63

EPS (TTM)-3.00

EPS (Forward)—

52W Range

13.6413% of range32.50

52W High32.50 PLN

52W Low13.64 PLN

Profitability

Gross Margin76.22%

Oper. Margin-98.71%

EBITDA Margin-74.71%

Profit Margin-162.61%

ROE-188.04%

ROA-45.10%

Growth

Revenue Growth-20.80%

Earnings Growth—

Cash Flow & Leverage

Operating CF-28.90M USD

CapEx (TTM)1.89M USD

FCF Margin14.20%

FCF Yield3.33%

Net Debt4.39M USD

Net Debt/EBITDA-0.28

Balance Sheet

Debt/Equity1.33

Current Ratio2.14

Quick Ratio1.95

Book Value/Sh1.23 PLN

Cash/Share3.23 PLN

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)29.90 PLN

Upside (mean)+86.9%

Target Range17.00 PLN – 46.00 PLN

17.00+86.9% to mean46.00

# Analysts5

Ownership

Shares Out.23.12M

Float14.49M

Insiders35.02%

Institutions24.28%

Technical

SMA 5016.67 (-4.0%)

SMA 20020.60 (-22.3%)

Beta0.40

S&P 52W Chg14.58%

Avg Vol (30d)37.77K

Avg Vol (10d)12.35K

Technical Indicators

RSI (14)43.7

MACD-0.1315

MACD Signal-0.1692

MACD Hist.+0.0377

BB Upper18.67 PLN

BB Middle15.75 PLN

BB Lower12.84 PLN

BB Width37.04%

ATR (14)0.7631 PLN

Vol Ratio (20d)0.29x